Exeltis is the result of the natural evolution and sustained growth of the CHEMO pharmaceutical business, an integrated health sciences group. It combines the Group’s know-how and experience with the innovative spirit of Exeltis, becoming a global organization with the capacity to discover, develop, produce and market medicinal products and medical devices that can help to improve the quality of life of millions of people worldwide.
People are our core concern and guiding force. In order to provide better therapeutic solutions and reach more people worldwide, Exeltis has taken its operations to every continent, giving even more patients rapid and effective access to our wide range of products.
With our innovative spirit, we use all our know-how, resources and human capital to develop solutions that meet patients’ unsatisfied needs.
Our endeavour to find new therapeutic alternatives had led us to join forces with other leading pharmaceutical companies that share our enthusiasm and to establish alliances in order to progress together in healthcare.
Our main mission is twofold: to make a difference in the everyday lives of millions of people, families and healthcare professionals by providing access to effective, first-class therapeutic solutions; and to improve healthcare in the future by conducting research and developing products, generating new and better therapies and through our passion and efforts to be present in every corner of the world
This wide and varied range includes products for some of the most important therapeutic areas, such as Women’s Health, Respiratory, Dermatology, Cardiology, Central Nervous System, Ophthalmology, Oncology, Gastroenterology, Infectious diseases and Endocrinology, among others.
Committed to caring for women at all stages of life (contraception, pregnancy, fertility, menopause), EXELTIS offers an extensive portfolio of gynaecological products to meet women’s reproductive health needs, treat associated conditions and improve female wellbeing and quality of life.
EXELTIS is a valued and trusted leading organization focused on the specialty respiratory area with our mission to advance the health of patients with respiratory disease by providing a broad range of oral and inhalation medicines and in investing in the development and acquisition of new and innovative treatment options
EXELTIS is a development-stage organization focused on developing and commercializing innovative new therapies in dermatology
One of the most important developments in this area is a new and unique medicinal product for the treatment of complex diabetic foot ulcers. A growing number of patients suffer from this condition, and this product treats an unaddressed aspect of this problem.
Exeltis is a consolidated, global organization which operates through a network of more than 30 subsidiaries, employing close to 4,000 professionals across over 40 countries.
Exeltis’ research activities are conducted in synergy with the potential afforded by CHEMO Group, the resources of our worldwide subsidiaries and the corporate research centre, Ladee Pharma Research Institute (LPRI), specialising in the research and development of new products from phase I to approval.
This active cooperation enables Exeltis to advance and generate a diverse project portfolio.